ANDA 212050, held by Adaptis. Colesevelam Hydrochloride.
As of Nov 15, 2026, ANDA 212050 (Colesevelam Hydrochloride), held by Adaptis, was first approved by FDA on Dec 4, 2020, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 4, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Colesevelam Hydrochloride625MG · tablet;oral | Colesevelam Hydrochloride | Rx |
| Sep 21, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 4, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters